Complement Activation Is Associated With Crescents in IgA Nephropathy.
complement
crescent
immunoglobulin A nephropathy (IgAN)
lectin pathway
urinary C4d
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
03
2021
accepted:
20
08
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Crescents, especially those found at a percentage greater than 50%, are often associated with rapid progression of kidney disease in IgA nephropathy (IgAN). The mechanism of crescents forming in IgAN is still unclear. In this study, we aimed to evaluate whether excess complement activation participates in the formation of crescents in IgAN. One hundred IgAN patients with various proportions of crescents-24 with 1%-24%, 27 with 25%-49%, 21 with 50%-74% 12 with more than 75%, and 16 without crescents-were included. Urinary concentrations of mannose-binding lectin (MBL), Bb, C4d, C3a, C5a, and soluble C5b-9 (sC5b-9) were measured at the time of biopsy. Receiver operating characteristic (ROC) curves were performed to evaluate predictive ability of renal survival for urine complement activation. In addition, historical C4d, C5b-9, and C3d were stained by immunohistochemistry. IgAN patients with more than 50% crescent formation showed higher complement activation levels than the other patients (urinary C3a/creatinine (C3a/Cr): 6.7295 ng/mg, interquartile range (IQR) 1.4652-62.1086 ng/mg vs. 0.1055 ng/mg, IQR 0-1.4089 ng/mg; urinary C5a/Cr: 15.6202 ng/mg, 4.3127-66.7347 ng/mg vs. 0.3280 ng/mg, IQR 0.0859-2.4439 ng/mg; urinary sC5b-9/Cr: 98.6357 ng/mg, 8.8058-1,087.4578 ng/mg vs. 1.4262 ng/mg, 0.0916-11.0858 ng/mg, all Excess complement activation may be involved in the formation of crescents, especially diffuse crescent formation, in patients with IgAN. Urinary C4d correlated with the proportion of crescents and was a potential biomarker for disease monitoring in crescentic IgAN.
Identifiants
pubmed: 34594322
doi: 10.3389/fimmu.2021.676919
pmc: PMC8477028
doi:
Substances chimiques
MBL2 protein, human
0
Mannose-Binding Lectin
0
Complement System Proteins
9007-36-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
676919Informations de copyright
Copyright © 2021 Wang, Xie, Li, Zhang, He, Wang, Lv and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pediatr Nephrol. 2014 Nov;29(11):2225-8
pubmed: 24924752
Am J Kidney Dis. 1988 Nov;12(5):348-52
pubmed: 3142256
Am J Kidney Dis. 1988 Nov;12(5):437-42
pubmed: 3055972
J Am Soc Nephrol. 2006 Jun;17(6):1724-34
pubmed: 16687629
J Am Soc Nephrol. 2015 Jul;26(7):1503-12
pubmed: 25694468
Nephron. 1998 Dec;80(4):408-13
pubmed: 9832639
Nat Rev Dis Primers. 2016 Feb 11;2:16001
pubmed: 27189177
J Am Soc Nephrol. 2017 Feb;28(2):691-701
pubmed: 27612994
J Am Soc Nephrol. 2013 Dec;24(12):2118-25
pubmed: 24029421
N Engl J Med. 2002 Sep 5;347(10):738-48
pubmed: 12213946
Clin Nephrol. 1984 Jun;21(6):335-40
pubmed: 6205804
Clin Kidney J. 2015 Oct;8(5):489-91
pubmed: 26413271
Am J Kidney Dis. 2001 Nov;38(5):1082-8
pubmed: 11684563
Am J Kidney Dis. 1988 Nov;12(5):340-7
pubmed: 3055955
Int J Clin Exp Pathol. 2014 May 15;7(6):3299-304
pubmed: 25031752
Kidney Int. 2018 Jul;94(1):16-18
pubmed: 29933843
Clin J Am Soc Nephrol. 2014 May;9(5):897-904
pubmed: 24578331